Drug Information

Drug (ID: DG00497) and It's Reported Resistant Information

• Name: Purine analogues
• Drug Resistance Disease(s):
  Disease(s) with Clinically Reported Resistance for This Drug (1 diseases)
  Chronic lymphocytic leukemia [ICD-11: 2A82]; [1]

Type(s) of Resistant Mechanism of This Drug

  UAPP: Unusual Activation of Pro-survival Pathway

Drug Resistance Data Categorized by Their Corresponding Diseases

ICD-02: Benign/in-situ/malignant neoplasm

Chronic lymphocytic leukemia [ICD-11: 2A82]

Drug Resistance Data Categorized by Their Corresponding Mechanisms

Unusual Activation of Pro-survival Pathway (UAPP)

Key Molecule: Cellular tumor antigen p53 (TP53) [1]

• Molecule Alteration: Mutation; .
• Resistant Disease: Chronic lymphocytic leukemia [ICD-11: 2A82.0]
• Experimental Note: Identified from the Human Clinical Data
• In Vitro Model: Bone marrow; Blood; Homo sapiens (Human); N.A.
• In Vivo Model: A retrospective survey in conducting clinical studies; Homo sapiens
• Experiment for Molecule Alteration: Sanger sequencing assay; Next-generation sequencing assay
• Experiment for Drug Resistance: karyotyping assay
• Mechanism Description: TP53 abnormalities lead to resistance to purine a.logues and are found in over 40% of patients with refractory chronic lymphocytic leukemia (CLL).

References

• Ref 1: TP53 mutations are early events in chronic lymphocytic leukemia disease progression and precede evolution to complex karyotypes. Int J Cancer. 2016 Oct 15;139(8):1759-63. doi: 10.1002/ijc.30222. Epub 2016 Jun 24.